Skip to main content

Fiscal Wizard · Single-issue tearsheet

GILD / Jun 22, 2026 Run #7711

GILD

Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Composite verdict

D 33.1 / 100
Bearish setup · Trend Following 13 drivers · 3 gates blocking
  • Coppock Curve
  • Vortex Signal
  • Sushi Roll
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 10th of 22 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -73%
Asset value $18.29Earnings power value $63.92Price $123.76

Priced above its no-growth earnings power value ($63.92/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

66.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
FCF Margin 88
Cash Conversion Cycle 0
Payout Ratio 83
PEGY 1

Technicals Bearish

0.1 / 100

Bearish setup leads (Coppock Curve, Vortex Signal, Sushi Roll); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Coppock Curve 15
Vortex Signal 17
Keltner Channels 22

Risk Gates

3 blocking 5 caution

3 guards active, 21 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Debt-to-Assets Caution

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GILD.